In the primary analysis, there were no significant treatment effects on mortality or risk of AKI for the following interventions: ACE inhibitors, dopamine agonists, erythropoietin, glycaemic control, goal-directed fluid therapy, loop diuretics, N-acetylcysteine, and corticosteroid therapy (Supplementary Table 3). The gene discussed is ACE; the disease is acute kidney injury.